Synchron Raises $200 Million to Advance Brain-Computer Interface
New York-based Synchron, a company specializing in brain-computer interface (BCI) technology, has secured $200 million in Series D funding. This round increases the company’s total capital raised to $345 million.
Funding Round and Investors
Double Point Ventures led the funding round, joined by existing backers ARCH Ventures, Khosla Ventures, Bezos Expeditions, NTI, and METIS. New participants include the Australian National Reconstruction Fund (NRF), T.Rx Capital, Qatar Investment Authority (QIA), K5 Global, Protocol Labs, and IQT.
Technology and Application
Synchron’s flagship product, Stentrode, is a non-surgical endovascular BCI designed to enhance mobility, communication, and independence for people living with paralysis. The device is implanted via a catheter procedure, interfacing with the motor cortex through blood vessels to convert brain signals into digital commands.
The BCI enables hands-free control of digital devices and has been implanted in 10 patients participating in clinical trials in Australia and the United States.
Plans for Fund Utilization
- Accelerate clinical trials and commercialization of the Stentrode BCI
- Expand in-house operations in New York, focusing on the cognitive AI division which develops models that learn from brain data
- Grow the engineering hub located in San Diego
"Synchron's Stentrode BCI is a non-surgical endovascular brain-computer interface platform designed to help improve mobility, communication and independence for individuals with paralysis."
With this funding, Synchron aims to bring its innovative brain-computer interface closer to wider clinical and commercial use.
Author’s summary: Synchron's $200M funding will fast-track trials and commercialization of its groundbreaking, non-surgical brain-computer interface, while expanding key operations in New York and San Diego.